Siremadlin (HDM201) is an orally bioavailable and selective inhibitor of the p53-MDM2 interaction designed by Novartis.1062 Currently, three clinical trials of siremadlin monotherapy or in combination with other drugs for the treatment of patients with advanced soft-tissue sarcoma (NCT05180695), AML (NCT05447663, NCT05155709) are ongoing. The gene discussed is MDM2; the disease is acute myeloid leukemia.